



DFIN CASE STUDY

How we helped a biotech company save hours on their SEC filings & increase reporting productivity

DFIN
ActiveDisclosure

 **ARCELLX™**

CORPORATE SNAPSHOT

Arcellx (NASDAQ: ACLX) is a clinical-stage biotech company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases.



\$729M

Amount of cash,
cash equivalents &
marketable securities



\$200M

New (or additional) investment
with Kite partnership expansion



February 2022

Went public and began
trading on NASDAQ

*Stats as of 2023

CHALLENGE

Streamline financial reporting to drive efficiencies.

Arcellx was managing through personnel turnover within its SEC reporting team, which led to challenges in maintaining consistency with their filing process.

Formatting disclosures were cumbersome, and issues with the formatting itself created inefficiency in validating document accuracy from their existing software. Arcellx was looking for an intuitive software that would save them time and streamline their financial reporting process.



SOLUTION

Fast, efficient & collaborative financial reporting

Arcellx turned to ActiveDisclosure as a time-saving reporting software that was intuitive and efficient. ActiveDisclosure provided new users with software targeted to their specific needs. They were pleased that new users were able to quickly use the tool without numerous time-consuming training sessions. The client also saved time with ActiveDisclosure’s linking feature. Being able to directly link to source data with version control features increased efficiency and supported data integrity. The team was able to collaborate efficiently on their filings, saving them time to focus on other projects.



BOOSTS COLLABORATION
Employees get up to speed quickly, with minimal training



INCREASES ACCURACY
100% error-free submissions



DRIVES EFFICIENCIES
Features like team and task notifications, commenting, XBRL tagging, Excel data linking and more

In our opinion, the unaudited interim condensed consolidated financial statements contain all adjustments (consisting of only normal recurring adjustments) necessary to present fairly, **T**

010-Cover
Josh Duncan Today - 11:16 AM

030-Balance Sheets
Stan Smith Today - 9:55 AM

040-Statements of Operations
Amy Flannery Today - 12:29 AM

Do you want to replace this workbook?

Original	Updated
11 Tables	11 Tables
105 Items	105 Items

Assets
Current Assets:
Cash
Accounts receiv
Prepaid expens
Total current as

“

As a former auditor, version control, formatting disclosures, and last-minute tweaks were always areas that added complexity to the audit process. We are pleased that ActiveDisclosure has helped us manage these processes and streamline our SEC reporting function, so we can smooth the path toward successful SEC reporting.”


Cecelia Xing

Associate Director of SEC Reporting
and Technical Accounting



Affordable ActiveDisclosure streamlines financial reporting

ActiveDisclosure is purpose-built and affordable with a robust set of advanced capabilities. Seamless integration with existing data sources and Excel data linking saves time, reduces errors and drives efficiencies. Faster, smarter and secure, ActiveDisclosure enables real-time collaboraton and accurate iXBRL tagging.



PURPOSE-BUILT

Core tools you need for successful SEC filing and financial reporting, without extra functionalities you'll never use



INNOVATIVE

Modern filing software with no costly add-ons, hidden costs or annual upsells



EFFICIENT

Streamlines reporting with features like Excel data linking, commenting, Intelligent iXBRL tagging, and more



CONNECTED

Simple integration to your current data sources and tech stack (e.g. Excel/MS Office, ERP)



EXPERT-DRIVEN

24/7/365 support by DFIN financial and SEC reporting experts dedicated to your success



SECURE

Best-in-class, built-in security tools ensure mitigation of data and risk



Get in touch

[DFINsolutions.com](https://dfinsolutions.com)

North America: +1 800 823 5304

APAC: +852 2522 3803

EMEA: +44 203 047 6100

LATAM: +55 11 3031 6327